Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results